Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Wednesday 16 May, 2007

VASTox plc

Re Agreement

VASTox plc
16 May 2007

                                   VASTox plc
                          ('VASTox' or 'the Company')



 VASTOX SIGNS CARBOHYDRATE DRUG DEVELOPMENT DEAL WITH US PHARMACEUTICAL COMPANY

          $450,000 Development Payment and 5% Royalty on Annual Sales



Oxford, UK, 16 May 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that it has signed a long-term commercial collaboration with
an undisclosed US pharmaceutical company that has total annual sales in excess
of $100 million.


The deal involves VASTox's wholly owned subsidiary, Dextra Laboratories 
('Dextra'), the carbohydrate drug discovery, process and development specialist, 
and is focused on the late-stage development of a healthcare product owned by 
the undisclosed company, that is due to launch in 2010.

Using its carbohydrate chemistry expertise and experience, Dextra will improve
the cost-efficiency of the manufacturing route for this product, which has
already been shown to be safe and efficacious during current clinical trials.

Under the terms of the agreement, VASTox will receive development payments of
$450,000, the majority of which will appear in the current financial year and a
5% annual royalty fee starting in 2009 as stocks of the product are built up
ahead of market launch. Annual sales of the product are predicted to peak in
2013 with royalty income for VASTox of around US$1 million at that time.

Steven Lee, PhD, CEO of VASTox commented 'This is a sizeable long-term
collaboration deal in one of our key areas of focus, carbohydrate chemistry, and
arises following the acquisition of Dextra earlier this year. With the
additional expertise that Dextra provides in this specialist area of chemistry,
VASTox can now successfully compete for these higher-value and longer-term
deals. Overall in 2007, this is VASTox's third long-term deal signed covering
the entire service business and as a Company, we are confident our world-leading
technologies and expertise will generate additional high-value deals in the
coming months.'


                                    - ends -



For more information please contact:


VASTox
Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray            Tel: +44 (0)207 638 9571






About VASTox plc


VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX



About Dextra Laboratories Ltd

Dextra Laboratories has an established world-class reputation in the area
carbohydrate chemistry and the Company operates a profitable custom synthesis
business with a turnover in excess of £700,000 in 2006. Dextra has an unrivalled
and innovative scientific expertise in the synthesis and manufacture of compound
targets across a range of therapeutic areas. These novel synthetic techniques
and strategies have generated a valuable library of complex and rare
carbohydrate compounds, which are available to clients through an on-line
catalogue business.

Dextra was acquired by VASTox plc in March 2007 and operates as a wholly owned
subsidiary.

Further information about the company is available at www.vastox.com

This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange